However, similar cases of new-onset colitis during IL-17A-inhibitor therapy [9, 10, 12, 13, 15] and data suggesting paradoxical colitis activity in Crohn’s disease patients [8] raise concerns. This evidence concerns the gene IL17A and Crohn disease.